What is it about?

In the past year, there have been numerous changes — lawmaking, regulations, and court decisions — influencing the life sciences industry. This panel will explore how these changes will impact the strategies and
decisions made during the IP due diligence process.

• Diving into patent eligibility for method of treatment claims in light of Vanda Pharmaceuticals
• Analyzing on-sale bar concerns in light of the Supreme Court’s grant of certiorari in Helsinn
• Deciphering evolving standards for demonstrating divided and induced infringement
• Asserting and defending against post-grant proceedings
  • Analysis and impact SAS Institute and related jurisprudence
  • Balancing conflicting burdens of proof between district courts and the PTAB
• Evaluating exclusivities and their effects on patent term
• Exploring the status of sovereign entities and IP challenges
• Revisiting inequitable conduct and unclean hands: Therasense, Gilead v. Merck, purge, and supplemental examination